Roche
$ROG (-0.63%) 🇨🇭hat in a phase 1 study with the weight loss tablet
CT-996 achieved positive results, with an average weight loss of 7.3 percent in four weeks.

CT-996 belongs to the class of GLP-1 weight loss drugs originally developed for the treatment of diabetes. diabetes treatment and reduce appetite.

These drugs also include the well-known weight loss injection Wegovy from Novo Nordisk
$NOVO B (+1.62%) and the drug Zepbound from Eli Lilly
$LLY (-0.09%).

One tablet form could significantly increase demand, which is why competitors are also working on such tablets.